METRIX

A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung Cancer

Brief summary

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases of which 60% are non-squamous (NSQ). This study will evaluate the prevalence of mesenchymal epithelial transition (MET) overexpression (OE) in adult participants with advanced or metastatic NSQ NSCLC. Archived tissue biopsies will be tested for MET OE and data from approximately 500 participants will be collected. No participants will be enrolled in this study. Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the study will be approximately 15 months. There is no additional burden for participants in this trial.

Observational study

Status:
Recruiting
Conditions:
Non Small Cell Lung Cancer
Enrollment:
500 patients
Protocol ID:
H24-281
Observational model:
Cohort
Time perspective:
Retrospective

Would you like to know more about this trial?

alert image Please note, participation in the clinical trial is open to patients with the disease or condition under investigation.
Yes, please contact me

Eligibility criteria

Participant attributes:
Male and Female

Age:

18 Years and older.

Inclusion Criteria:

- Previously consented and/or prospective collection of consent for research use of
banked biological materials and clinical data.

- Confirmed advanced and/or metastatic non-squamous (NSQ) non-small cell lung cancer
(NSCLC).

- Has formalin-fixed paraffin-embedded (FFPE) tissue collected since 2019.

Exclusion Criteria:

- Specimens collected before 2019.

- Insufficient specimen tissue for testing.

- Insufficient specimen quality (e.g., not 4-5 µm in thickness) which precludes testing.

- Adenosquamous and sarcomatous histologies of NSCLC.

All the cities where the clinical studies are located

Saskatoon - S7N 0W8

Nova Scotia

Saskatchewan